Predictors of Hypertension Remission and Recurrence After Bariatric Surgery

Benaiges, David; Sagué, M.; Roux, Juana A. Flores‐Le; Pedro‐Botet, Juan; Ramón, José́; Villatoro, Montserrat; Chillarón, Josep; Pera, Manuel; Más, Antonio Juan; Grande, Luís; Goday, Albert

doi:10.1093/ajh/hpv153

Cited by 61 publications

(37 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These molecules were shown to Hypertension Remission contribute to vascular stiffness, which can favour hypertension development and poor CV outcome. 32,33 Unfortunately, we did not perform a long-term follow-up to confirm this finding. 24 Our results may be judged as "paradoxical," since we previously demonstrated that high baseline hs-CRP predicts good clinical response to bariatric surgery in terms of diabetes remission and reduction in visceral fat.…”

Section: Discussionmentioning

confidence: 88%

Baseline hs‐CRP predicts hypertension remission in metabolic syndrome

Carbone

Elia

Casula

et al. 2019

Eur J Clin Investigation

View full text Add to dashboard Cite

Background: Inflammation, overweight and other cardiovascular risk factors might negatively impact on hypertension remission in metabolic syndrome (MetS), independently of the pharmacological treatment. Here, the potential influence of systemic inflammation (assessed by serum high-sensitivity C-reactive protein [hs-CRP]) on hypertension remission will be investigated in a cohort of hypertensive patients with MetS. Material and Methods: Hypertensive patients with MetS (n = 100) were enrolled, treated under current behavior/dietary/pharmacological recommendations and followed up for 12 months. All patients received medications and nutritional advice based on Mediterranean-like dietary pattern in addition to psychological and physicalactivity counselling. At baseline (T0), 6 (T1) and 12 (T2) months of follow-up, clinical data, haematological and biochemical profiles and serum hs-CRP were measured. Results: As compared to T0, at T2 patients displayed improvements in anthropometric and metabolic profiles. At T2, the hypertension remission rate was 13.0%. Serum hs-CRP did not change overtime in the overall cohort. Surprisingly, patients who experienced hypertension remission were less treated with antihypertensive drugs, but developed a weak improvement in anthropometric measures during follow-up.The hypertension remission group had lower baseline levels of hs-CRP as compared to non-remission. Low baseline hs-CRP (<2 µg/mL, cut-off value identified by ROC curve) predicted hypertension remission, independently of antihypertensive treatment implementation, baseline systolic blood pressure and waist circumference improvement. Conclusions: Remission of hypertension in MetS is independently associated with baseline low CRP levels, which might suggest a critical role for inflammation in sustaining high blood pressure levels. K E Y W O R D SC-reactive protein, hypertension, inflammation, metabolic syndrome, obesity, overweight

show abstract

Section: Discussionmentioning

confidence: 88%

Baseline hs‐CRP predicts hypertension remission in metabolic syndrome

Carbone

Elia

Casula

et al. 2019

Eur J Clin Investigation

View full text Add to dashboard Cite

show abstract

“…Although a comprehensive discussion on bariatric surgery is beyond the scope of our review, we need to mention that it might become an appropriate treatment option for some patients. Commonly used bariatric procedures include gastric banding, Roux-en-Y gastric bypass, and sleeve gastrectomy [124][125][126][127][128] . On average, weight loss with bariatric surgery is greater than with nonsurgical interventions, around 15-35% depending on the procedure [120,[129][130][131][132] .…”

Section: Traditional Approachmentioning

confidence: 99%

“…Although bariatric surgery may result in greater weight loss than other obesity interventions, it is an invasive procedure that requires important long-term commitment and follow-up by patients and health-care teams. Consequently, current treatment recommendations reserve bariatric surgery for people with BMI ≥ 40 or ≥ 35 with obesity-associated complications [120,[126][127][128][133][134][135] . Those who are interested in further updating their knowledge on current alternatives for obesity treatment will find a recent review to be a great help [121,136] .…”

Section: Traditional Approachmentioning

confidence: 99%

White Adipose Tissue and Circadian Rhythm Dysfunctions in Obesity: Pathogenesis and Available Therapies

2016

View full text Add to dashboard Cite

A combined neuroendocrine, metabolic, and chronobiological view can help to better understand the multiple and complex mechanisms involved in obesity development and maintenance, as well as to provide new effective approaches for its control and treatment. Indeed, we have currently updated data on the whole adipogenic process involved in white adipose tissue (WAT) mass expansion, namely due to a mechanism whereby WAT cells become hypertrophic, thus inducing a serious local (WAT) inflammatory condition that in turn, will impair not only the cross-talk between the hypothalamus and the WAT, but also favoring the development of deep and widespread neuroendocrine-metabolic dysfunction. Moreover, we also have revisited the circadian clock genes involved in dysfunctional WAT mass expansion and the mechanisms that may lead to obesity development, including early metabolic dysfunctions, enhanced oxidative stress and distorted energy homeostasis. The epigenetic changes of clock genes driving metabolic disease and obesity development have also been included in this review. Finally, we have also underlined the relevance of metabolic homeostasis regulation by central and peripheral organ clocks, sleep disturbances, nutrients, and feeding time, as key factors in obesity development as well as both, classical and chronotherapeutic approaches for its prevention and treatment.

show abstract

“…Both procedures proved equally effective in the resolution of comorbidities and the weight loss. 13 This change, both in weight and comorbidities, directly impacts mortality, with a decrease between 29 and 40% and with improvements in terms of life expectancy. 14 We know that obesity accounts for between 2 and 7% of the overall health costs of a country, which can translate, in the USA, into 100 billions of dollars each year.…”

Section: Discussionmentioning

confidence: 99%

“…[22][23][24] A Swedish study showed more benefits with the bypass, although it is worth mentioning that this study did not include the gastric sleeve. 13 Bariatric surgery has proved to be the most effective treatment in management of metabolic syndrome. 25 A decrease of more than 50% of the patient's excess weight has a significant impact on the resolution of this pathology and the type of surgery undertaken does not affect this result; in our cohort, there was a loss of 30% of the patient's excess weight in the 1st month, leading to a significant improvement of their metabolic syndrome.…”

Section: Discussionmentioning

confidence: 99%